| dc.creator | McCarthy, Antonio Desmond | |
| dc.creator | Cortizo, Ana María | |
| dc.creator | Sedlinsky, Claudia | |
| dc.date | 2016 | |
| dc.date | 2020-10-09T16:28:11Z | |
| dc.date.accessioned | 2023-07-14T22:45:58Z | |
| dc.date.available | 2023-07-14T22:45:58Z | |
| dc.identifier | http://sedici.unlp.edu.ar/handle/10915/106633 | |
| dc.identifier | http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4807302&blobtype=pdf | |
| dc.identifier | https://www.wjgnet.com/1948-9358/full/v7/i6/122.htm | |
| dc.identifier | issn:1948-9358 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/7448124 | |
| dc.description | Patients with long-term type 1 and type 2 diabetes mellitus (DM) can develop skeletal complications or “diabetic osteopathy”. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatments can secondarily affect bone metabolism. Adenosine monophosphate-activated protein kinase (AMPK) modulates multiple metabolic pathways and acts as a sensor of the cellular energy status; recent evidence suggests a critical role for AMPK in bone homeostasis. In addition, AMPK activation is believed to mediate most clinical effects of the insulin-sensitizer metformin. Over the past decade, several research groups have investigated the effects of metformin on bone, providing a considerable body of pre-clinical (<i>in vitro</i>, <i>ex vivo</i> and <i>in vivo</i>) as well as clinical evidence for an anabolic action of metformin on bone. However, two caveats should be kept in mind when considering metformin treatment for a patient with type 2 DM at risk for diabetic osteopathy. In the first place, metformin should probably not be considered an anti-osteoporotic drug; it is an insulin sensitizer with proven macrovascular benefits that can secondarily improve bone metabolism in the context of DM. Secondly, we are still awaiting the results of randomized placebo-controlled studies in humans that evaluate the effects of metformin on bone metabolism as a primary endpoint. | |
| dc.description | Facultad de Ciencias Exactas | |
| dc.format | application/pdf | |
| dc.format | 122-133 | |
| dc.language | en | |
| dc.rights | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.rights | Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) | |
| dc.subject | Ciencias Exactas | |
| dc.subject | Ciencias Médicas | |
| dc.subject | Diabetes Mellitus | |
| dc.subject | Osteoporosis | |
| dc.subject | bone fractures | |
| dc.subject | metformin | |
| dc.subject | AMP-activated kinase | |
| dc.title | Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy? | |
| dc.type | Articulo | |
| dc.type | Articulo | |
